Tesofensine (500mcg)
Tesofensine is a triple monoamine reuptake inhibitor (serotonin, norepinephrine, dopamine) initially developed for neurodegenerative diseases but found to cause significant weight loss. It is administered orally or subcutaneously.
Reviewed by the AllPeptides.eu Editorial Team·Last reviewed: 2026-06-16
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer
How It Works
Tesofensine inhibits the reuptake of serotonin, norepinephrine, and dopamine in the brain, reducing appetite and possibly increasing basal metabolism. In Phase IIb clinical trials, patients with obesity lost 6–13% of their body weight over 24 weeks.
Quick Start
- Form: 500 mcg capsule or lyophilized vial.
- Typical dose: 250–500 mcg daily.
- Administration: Oral or subcutaneous (investigational).
- Storage: Room temperature (capsule) or 2–8 °C (vial).
Typical Dosing (500 mcg capsule/vial)
Route: Oral or Subcutaneous | Frequency: Once daily
| Week | Dose | Units (per injection) |
|---|---|---|
| Weeks 1–2 | 250 mcg | Half capsule or appropriate units |
| Weeks 3+ | 500 mcg | 1 capsule / full dose |
Once daily, preferably in the morning. The 500 mcg dose corresponds to the Phase IIb study.
Related compounds
Reconstitution Steps
- If using lyophilized form, reconstitute according to manufacturer's instructions.
- Capsules: no reconstitution needed.
Protocol Overview
- Goal: Weight loss through appetite reduction and increased energy expenditure.
- Mechanism: Triple reuptake inhibition (5-HT, NE, DA).
- Schedule: Daily, continuous use.
Dosing Protocol
- Initiation: 250 mcg daily × 2 weeks.
- Maintenance: 500 mcg daily.
- Duration: 12–24 weeks (based on Phase IIb studies).
- Break between cycles: Gradual reduction before discontinuation. Monitor weight after stopping.
Washout & Cycle Restart
When can I restart?
Gradual reduction before discontinuation. Monitor weight after stopping.
Minimum wait period: 4 weeks
Storage Instructions
- Capsules: Room temperature, away from moisture.
- Vial: 2–8 °C after reconstitution.
Important Notes
- NOT approved — Phase IIb completed, Phase III ongoing.
- Differs from GLP-1 agonists — central action on neurotransmitters.
- May increase heart rate and blood pressure.
- Contraindicated in patients with uncontrolled hypertension.
- Interactions with MAOIs and antidepressants.
Potential Benefits & Side Effects
Potential Benefits:
- Significant weight loss (6–13% in Phase IIb).
- Appetite reduction.
- Possible increase in metabolism.
- Mood improvement (dopaminergic action).
Potential Side Effects:
- Increased heart rate.
- Dry mouth.
- Insomnia.
- Constipation.
- Nausea.
⚠️ Serious Warnings & Long-Term Risks
The following warnings are based on published literature, FDA labels, and post-marketing surveillance. They do not constitute medical advice. Consult a healthcare professional.
Increased heart rate & blood pressure
Tesofensine (triple reuptake inhibitor — 5-HT/NA/DA) caused dose-dependent increase in heart rate (+7-8 bpm) and blood pressure. Contraindicated in uncontrolled hypertension.
📄 TIPO-1 & TIPO-2 Phase 2 Trials — Lancet 2008Psychiatric adverse events
As a monoamine reuptake inhibitor, may cause insomnia, anxiety, mood changes. Contraindicated in patients with psychiatric history or on MAOIs.
📄 Phase 2 Safety Data — Obesity Reviews 2010References
- Tesofensine Phase IIb: Weight Loss in Obese Patients (TIPO-1) — The Lancet (2008) — Tesofensine Phase IIb: weight loss in obese patients (TIPO-1)
View Source - Int J Obes — Tesofensine mechanism and metabolism
View Source - Obesity Reviews — Review of tesofensine as an anti-obesity agent
View Source
Recommended Supplements
Vitamin B12 (Methylcobalamin)
Vitamin D3 + K2
Omega-3 Fish Oil (EPA/DHA)
Protein / Collagen
Fiber Supplement (Psyllium)
External Sources & Regulatory Status
Regulatory Approvals
Obesity
Obesity
Phase II clinical trials
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
Continue Your Research
Explore tools and guides related to this protocol.
Important Disclaimer
The content of this website is provided exclusively for informational and educational purposes within the context of research literature.
Read the full Disclaimer →